Coherent Diagnostic Technology, a developer of optical coherence tomography (OCT) systems for medical imaging applications, is changing its name to LightLab Imaging. Paul Magnin, president and CEO of LightLab, said his company predicts that light will
Coherent Diagnostic Technology, a developer of optical coherence tomography (OCT) systems for medical imaging applications, is changing its name to LightLab Imaging. Paul Magnin, president and CEO of LightLab, said his company predicts that light will have an important role in imaging and medicine, and the new name better captures this movement.
Systems using OCT have already been deployed for use in ophthalmic applications (SCAN 9/1/99). The FDA is reviewing several LightLab Imaging products using OCT for market clearance. In addition, the company has products in the pipeline that it will submit to the FDA in the near future, according to a company spokesperson.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.